mHSPC COE

Sharing Care within Private Clinics for Patients with Newly Diagnosed mHSPC - David Morris & Benjamin Garmezy Details Alicia Morgans hosts a multidisciplinary discussion with David Morris and Benjamin Garmezy focusing on the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Morris highlights the increasing trend of referring patients with high-volume Gleason 8 disease and metastatic cancer to tertiary care centers. He emphasizes the importance of early discussions about intens...
Triple-Drug Therapies Usher in Sea Change for Men With High-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen discuss the amended AUA guidelines for advanced prostate cancer, focusing on triplet therapy for metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castrate-resistant prostate cancer (M0 CRPC). They delve into the role of triplet therapy in mHSPC, examining its benefits across disease volume and risk subgroups, as evidenced by the ARASENS and PE...
Chinese Subgroup Analysis Reveals Both Similar and Distinct Responses to Novel Darolutamide Combination Therapy - Yao Zhu Details Dingwei Ye introduces a conversation with Alicia Morgans, featuring insights from Professor Yao Zhu, Deputy Executive Director of Urology Surgery at Fudan University Shanghai Cancer Center, on the recent findings from the ARASENS study in the Chinese population. Professor Zhu shares that the study included 202 Chinese patients, about one-seventh of the total, revealing significant efficacy of daro...
ARASENS Phase 3 Clinical Trial Regimen Demonstrates Significant Survival Benefit for Chinese Patients - Yong YANG Details Alicia Morgans speaks with Yong YANG about prostate cancer in China, focusing on the ARASENS Phase 3 Clinical Trial. Professor YANG reveals that prostate cancer incidence in China is about 12 per 10,000, with a lower five-year survival rate than in the USA, largely due to late diagnoses. Approximately 60% of patients initially presented with metastasis. Treatment follows international guidelines a...
Combination Therapy Jolts 'Exhausted' Immune Cells Awake to Attack Tumors in Patients with Metastatic Castration-Sensitive Prostate Cancer - Jessica Hawley & Aleksandar Obradovic Details Andrea hosts Jessica Hawley and Aleksandar Obradovic to discuss their study, published in Cancer Cell, which explores the effects of combining Anti-PD-1 immunotherapy with Androgen Deprivation Therapy (ADT) in metastatic castration-sensitive prostate cancer. The research, part of the PRIME-CUT Study, used advanced techniques like single-cell RNA sequencing and quantitative immunofluorescence to an...
Harnessing Tumor Biology to Improve Outcomes in Advanced Hormone-Sensitive Prostate Cancer - Gerhardt Attard Details Gerhardt Attard discusses advancing the treatment of advanced hormone-sensitive prostate cancer through biological research. Dr. Attard's work focuses on two main areas: analyzing tumor samples from clinical trials to understand the biology driving cancer aggressiveness and identifying new therapeutic targets. He emphasizes the need for prognostic tests to tailor treatments, especially considering...
Deep PSA Response Following Addition of Darolutamide to ADT and Docetaxel in ARASENS - Fred Saad Details Zach Klaassen hosts a discussion with Fred Saad about the ARASENS data and its transformative impact on prostate cancer treatment. This conversation primarily explores the correlation between a rapid, deep, and durable PSA response and excellent patient outcomes. Dr. Saad underlines the biological significance of a decline in PSA, noting how patients who achieve undetectable PSA levels significant...
mHSPC Network Meta-Analysis on the Use of Intensified Treatments - Fred Saad Details Alicia Morgans engages with Fred Saad to discuss a network meta-analysis concerning treatments for patients with metastatic hormone-sensitive prostate cancer. They explore the controversies surrounding the most effective treatment for newly diagnosed disease, considering factors like disease volume and whether it's recurrent or de novo. Dr. Saad explains the diminishing role of ADT alone, emphasiz...
Meta-Analysis Sheds Light on Optimal Treatment Strategies for Metastatic Hormone-Sensitive Prostate Cancer - Benjamin Maughan Details Alicia Morgans interviews Ben Maughan focusing on a published network meta-analysis involving 11 randomized control trials for patients treated for metastatic hormone-sensitive prostate cancer. The analysis stirred significant debate on Twitter and sought to establish whether triplet therapy was superior to other approaches like ADT plus docetaxel and ADT plus an AR-targeted therapy. Dr. Maughan e...
Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer, Advances and Barriers – Cora Sternberg Details In this video, Alicia Morgans speaks with Cora Sternberg about the evolution of prostate cancer care over the last 20 years, highlighting recent advances and current barriers. Prostate cancer research includes advancements in novel hormonal therapies such as androgen deprivation therapy with a novel hormonal therapy or docetaxel improving overall survival in its metastatic hormone-sensitive stage....

mHSPC COE

Login